Interrelationship Between Primary Aldosteronism and Obstructive Sleep Apnea in Hypertension: Implications for Organ Damage and Treatment Options

PA, the most prevalent endocrine cause of hypertension, occurs in about 5-10% of all hypertensive patients and up to 20% in those with resistant hypertension. It is linked to greater cardiovascular and renal target organ damage compared to essential hypertension. OSA introduces intermittent hypoxia and sympathetic activation that can further deteriorate vascular and cardiac function. The interplay between PA and OSA is most pronounced in individuals who are obese or have metabolic syndrome, although varying diagnostic criteria can complicate their relationship.

On a clinical level, PA commonly presents with resistant hypertension, and hypokalemia can occur, but most patients are normokalemic. Diagnostic approaches typically involve the aldosterone-to-renin ratio and other biochemical tests, although some cases may require further confirmatory testing and imaging.

Both PA and OSA have been associated with detrimental changes in cardiovascular and renal health. Aldosterone's action can lead to left ventricular hypertrophy and renal injury, while OSA's intermittent hypoxia and sympathetic surges can promote similar outcomes. The overlap of these conditions necessitates careful assessment and treatment of each disorder, with strategies including proper PA management—such as adrenalectomy for unilateral cases or mineralocorticoid receptor antagonists for bilateral cases—and appropriate OSA treatment, primarily through continuous positive airway pressure (CPAP) therapy.

Despite existing treatments, the long-term cardiovascular, renal, and cerebrovascular outcomes following combined management strategies remain uncertain, indicating the need for further research. Effective management of both PA and OSA may require a multidisciplinary approach to optimize outcomes for patients suffering from hypertension.